Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
Digestive and Liver Disease, Volume 53, No. 3, Year 2021
Notification
URL copied to clipboard!
Description
Background: It is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19. Objectives: This observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders. Methods: This multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed. Results: 1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28–0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03–0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02–1.17). Conclusion: IBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients. © 2021 Editrice Gastroenterologica Italiana S.r.l.
Authors & Co-Authors
Maconi, Giovanni
Italy, Milan
Università Degli Studi Di Milano
Bosetti, C.
Italy, Milan
Istituto Di Ricerche Farmacologiche Mario Negri
Boyapati, Ray K.
Australia, Clayton
Monash University
Lenti, Marco Vincenzo
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Bezzio, Cristina
Italy, Rho
Ospedale Di Rho
Ricci, Chiara
Italy, Brescia
Università Degli Studi Di Brescia
Italy, Brescia
Spedali Civili Di Brescia
Massari, Alessandro
Italy, Milan
Università Degli Studi Di Milano
Di Sabatino, Antonio D.
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Saibeni, Simone
Italy, Rho
Ospedale Di Rho
Ferretti, Francesca
Italy, Milan
Università Degli Studi Di Milano
Rizzardini, Giuliano
Italy, Milan
Asst Fatebenefratelli Sacco
Galli, Massimo
Italy, Milan
Asst Fatebenefratelli Sacco
Ardizzone, Sandro
Italy, Milan
Università Degli Studi Di Milano
Statistics
Citations: 21
Authors: 13
Affiliations: 10
Identifiers
Doi:
10.1016/j.dld.2020.12.013
ISSN:
15908658
Research Areas
Covid
Study Design
Randomised Control Trial
Cross Sectional Study
Participants Gender
Male